focus -WSS

focus

author：focus 2025-09-30 20:46:47 - browse：2

A person picking up medication at a drive through pharmacy window – biotech and pharma coverage from STAT — Adobe

On Tuesday morning, the Department of Health and Human Services unveiled its long-awaited list of the 10 medicines that will be subject to price negotiation in 2026 under the Inflation Reduction Act.

This will mark the first time that Medicare, the government program for paying for health care for older Americans, will have any ability to use its vast size to negotiate for lower prices. It’s not yet clear how big the discounts on these 10 drugs will be, or even if the law will hold up to multiple legal challenges from the pharmaceutical industry. It’s also not clear, as critics from the drug industry have noted, whether any savings to the government will be passed on to consumers.

Still, the naming of 10 medicines is a milestone, and a point to start appraising the impact of the law. The landscape here is complicated. No one really knows how the IRA’s price negotiation process will play out over the short and long term, and many companies who had products named were spared in other ways, with products many industry watchers expected to see on the list absent. Here is STAT’s assessment of who has won and lost.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Juul documents reveal insider tactics on political lobbying

WSS

Congress must protect the remaining independent doctors

How AI helped researchers track recovery from depression

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Ukraine and a new approach to mental health in war

Abbott's new heart device gets FDA advisory panel nod

Lasker Awards 2023: Winners in biomedical research

hotspot

focus

focus

https://cbu01.alicdn.com/img/ibank/2017/704/324/4480423407_1438817008.220x220xz.jpg

Readout LOUD podcast: possible new ALS drug, artificial wombs

Hepatitis C has a cure — but many Americans still lack access to it

Intarcia’s device

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Why don't Americans have at

Continuity nursing helped my family in our darkest PICU moments

STAT Virtual Event: Putting AI to the Test

Psychedelics group wrestles with new pharma identity

Tome Biosciences co

explore

Experts study whether long Covid risk adds up with each reinfection

Tome Biosciences co

It's been 20 years since Dolly the sheep. Where's my clone?

Latigo launches with $135 million for Vertex

AMAs digital advisors table RPM coding reform proposal, again

Juul documents reveal insider tactics on political lobbying

focus

leisure time

focus

focus